VOYA Investment Management
TCRX icon

VOYA Investment Management’s TScan Therapeutics TCRX Stock Holding History

VOYA Investment Management’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-12,786
Closed -$38.9K – 2726
2024
Q4 		$38.9K Sell
12,786
-1,125
-8% -$5.1K ﹤0.01% 2711
2024
Q3 		$69.3K Buy
13,911
+308
+2% +$1.86K ﹤0.01% 2732
2024
Q2 		$79.6K Buy
+13,603
New +$107K ﹤0.01% 2725

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
CC
Checkpoint Capital San Francisco, California $279M AUM 45.74% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

VOYA Investment Management's TCRX Position: Q1 2025 in Review

VOYA Investment Management sold out of TScan Therapeutics (TCRX) in Q1 2025, closing a stake of 12,786 shares — an estimated $38.9K sold.

VOYA Investment Management first reported a position in TCRX in Q2 2024 and held it in 3 quarters. The position peaked at $79.6K in Q2 2024. 92 funds tracked by Wall St. Rank hold TCRX as of Q1 2025.

  • VOYA Investment Management reported no remaining TScan Therapeutics position as of Q1 2025 after selling out during the quarter.
  • VOYA Investment Management sold 12,786 TScan Therapeutics shares in Q1 2025, an estimated $38.9K.
  • VOYA Investment Management first reported a position in TScan Therapeutics in Q2 2024 and held it in 3 quarters.
  • VOYA Investment Management's TScan Therapeutics position peaked at $79.6K in Q2 2024.
  • 92 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2025.

Based on VOYA Investment Management's 13F filing for Q1 2025, filed 15 May 2025.